Evidence map›Paper›PMID 33586465›Full record

ArticleJournal of the American Heart Association2021

Lower Risk of Dementia in Patients With Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Population-Based Cohort Study.

Jin-Yi Hsu, Peter Pin-Sung Liu, An-Bang Liu, Shu-Man Lin, Huei-Kai Huang, Ching-Hui Loh

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. The neurocognitive effects of atrial fibrillation: benefits of the ABC pathway.European heart journal. Cardiovascular pharmacotherapy · 2023
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jin-Yi HsuCenter for Aging and Health Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation Hualien Taiwan.
Peter Pin-Sung LiuCenter for Aging and Health Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation Hualien Taiwan.
An-Bang LiuSchool of Medicine Tzu Chi University Hualien Taiwan.
Shu-Man LinSchool of Medicine Tzu Chi University Hualien Taiwan.
Huei-Kai HuangSchool of Medicine Tzu Chi University Hualien Taiwan.
Ching-Hui LohCenter for Aging and Health Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation Hualien Taiwan.
Tzu Chi University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background A higher risk of developing dementia is observed in patients with atrial fibrillation (AF). Results are inconsistent regarding the risk of dementia when patients with AF use different anticoagulants. We aimed to investigate the risk of dementia in patients with AF receiving non-vitamin K antagonist oral anticoagulants (NOACs) compared with those receiving warfarin. Methods and Results We conducted a nationwide population-based cohort study of incident cases using the Taiwan National Health Insurance Research Database. We initially enlisted all incident cases of AF and then selected those treated with either NOACs or warfarin for at least 90 days between 2012 and 2016. First-ever diagnosis of dementia was the primary outcome. We performed propensity score matching to minimize the difference between each cohort. We used the Fine and Gray competing risk regression model to calculate the hazard ratio (HR) for dementia. We recruited 12 068 patients with AF (6034 patients in each cohort). The mean follow-up time was 3.27 and 3.08 years in the groups using NOACs and warfarin, respectively. Compared with the HR for the group using warfarin, the HR for dementia was 0.82 (95% CI, 0.73-0.92;

Indexed as

Population SurveillanceAdministration, OralAgedAnticoagulantsAtrial FibrillationDementiaFemaleFollow-Up StudiesHumansIncidenceMaleRetrospective StudiesRisk AssessmentRisk FactorsStrokeSurvival RateAnticoagulantsWarfarinatrial fibrillationdementianon‐vitamin K antagonist oral anticoagulantswarfarin

Identifiers

PMID33586465
PMCPMC8174264
OpenAlexW3130689819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.